Sirnaomics Ltd (HKG: 2257) has entered into a strategic partnership with China’s Hualan Biological Engineering Inc., (SHE: 002007), to enhance the clinical development and commercialization of Sirnaomics’ respiratory syncytial virus (RSV) mRNA vaccine, RV-1770, in China. Under the agreement, Hualan will oversee clinical development, industrialization, and commercialization of the vaccine candidate in China, with Sirnaomics receiving an undisclosed amount in upfront and milestone payments, in addition to royalties on future sales.
RV-1770 is an innovative mRNA vaccine containing a proprietary lipid nanoparticle formulation designed to prevent RSV virus infection in adults. The vaccine features a unique AI-enhanced sequence skeleton design and utilizes recently isolated clinical strains of RSV. In preclinical cotton mouse model studies, RV-1770 has shown both immune response and neutralizing effects on RSV subtype A and B virus strains, along with a favorable safety profile. The vaccine candidate received clearance for clinical trials in the US in December of the previous year.- Flcube.com
